elliquence and Implanet jointly announced a strategic agreement for U.S. distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine surgery.
elliquence’s Surgi-Max Ultra platform delivers effective soft tissue dissection and coagulation in endoscopic procedures, while Implanet’s Olea technology enables precise and efficient bone cutting. By combining the Implanet’s bone scalpel with elliquence’s Surgi-Max and its bipolar Trigger-Flex technology, surgeons are now equipped with a synergy of bone and soft tissue management tools. Integrating the ultrasonic bone scalpel allows for safer, more controlled bone removal, preserving neural structures and minimizing soft tissue damage—further enhancing the precision and outcomes of minimally invasive spine surgery.
“We’re honored to be engaging with our like-minded colleagues to further introduce the surgeon community to first-of-its-kind endoscopic blade technology,” stated Max Painter, Vice President and General Manager of Implanet America. “It’s rewarding to be able to team with other innovation-driven companies to expand the reach of this innovative technology and provide the broader surgeon community with game-changing solutions.”
“This partnership is an endorsement of the clinical value of our technology,” added Ludovic Lastennet, Implanet’s Chief Executive Officer. “This type of partnership fits with the medium-term development plan we announced in the middle of 2023 and the partnership with SanYou Medical. It demonstrates our ability to market new technologies with a newly formed seasoned team in the US. With this team on board, we will be able to launch new mainstream product lines in the short term.”
elliquence and Implanet jointly announced a strategic agreement for U.S. distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine surgery.
elliquence’s Surgi-Max Ultra platform delivers effective soft tissue dissection and coagulation in endoscopic procedures, while Implanet’s Olea technology enables precise and efficient bone...
elliquence and Implanet jointly announced a strategic agreement for U.S. distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine surgery.
elliquence’s Surgi-Max Ultra platform delivers effective soft tissue dissection and coagulation in endoscopic procedures, while Implanet’s Olea technology enables precise and efficient bone cutting. By combining the Implanet’s bone scalpel with elliquence’s Surgi-Max and its bipolar Trigger-Flex technology, surgeons are now equipped with a synergy of bone and soft tissue management tools. Integrating the ultrasonic bone scalpel allows for safer, more controlled bone removal, preserving neural structures and minimizing soft tissue damage—further enhancing the precision and outcomes of minimally invasive spine surgery.
“We’re honored to be engaging with our like-minded colleagues to further introduce the surgeon community to first-of-its-kind endoscopic blade technology,” stated Max Painter, Vice President and General Manager of Implanet America. “It’s rewarding to be able to team with other innovation-driven companies to expand the reach of this innovative technology and provide the broader surgeon community with game-changing solutions.”
“This partnership is an endorsement of the clinical value of our technology,” added Ludovic Lastennet, Implanet’s Chief Executive Officer. “This type of partnership fits with the medium-term development plan we announced in the middle of 2023 and the partnership with SanYou Medical. It demonstrates our ability to market new technologies with a newly formed seasoned team in the US. With this team on board, we will be able to launch new mainstream product lines in the short term.”
Copy to clipboard 
